Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin

Vascular Pharmacology

Volumn 59, Issue 3-4, 2013, Pages 112-118

  Han, J ^a,b   Hiebert, L M ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Diabetic cardiovascular complications; Endothelial cells; Heparanase; Heparin; Syndecan

Indexed keywords

GLUCOSE; HEPARANASE; HEPARIN; INSULIN; MESSENGER RNA; PERLECAN; RNA; SYNDECAN;

AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

C(T); CALCIUM AND MAGNESIUM-FREE DULBECCO'S PHOSPHATE-BUFFERED SALINE; CMF-DPBS; DIABETIC CARDIOVASCULAR COMPLICATIONS; ECM; ECS; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; GAGS; GLYCOSAMINOGLYCANS; HAECS; HEPARAN SULFATE; HEPARAN SULFATE PROTEOGLYCANS; HEPARANASE; HEPARIN; HS; HSPGS; HUMAN AORTIC ENDOTHELIAL CELLS; PAECS; PORCINE AORTIC ENDOTHELIAL CELLS; SYNDECAN; THRESHOLD CYCLE;

AORTA; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLUCOSE; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; HEPARITIN SULFATE; HUMANS; INSULIN; PROTEOGLYCANS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNDECANS;

EID: 84885305158     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2013.08.001     Document Type: Article

References (48)

1. Banfi C., Eriksson P., Giandomenico G., Mussoni L., Sironi L., Hamsten A., et al. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes 2001, 50:1522-1530.
2. Bar-Ner M., Eldor A., Wasserman L., Matzner Y., Cohen I.R., Fuks Z., et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987, 70:551-557.
3. Black A.R., Black J.D., Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001, 188:143-160.
4. Bollineni J.S., Alluru I., Reddi A.S. Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Curr Eye Res 1997, 16:127-130.
5. Ceriello A. The emerging challenge in diabetes: the "metabolic memory". Vascul Pharmacol 2012, 57:133-138.
6. Cohen I.R., Grassel S., Murdoch A.D., Iozzo R.V. Structural characterization of the complete human perlecan gene and its promoter. Proc Natl Acad Sci U S A 1993, 90:10404-10408.
7. Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 1985, 40:747-758.
8. Edwards I.J., Wagner J.D., Vogl-Willis C.A., Litwak K.N., Cefalu W.T. Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovasc Diabetol 2004, 3:6.
9. Elliott T.G., Cockcroft J.R., Groop P.H., Viberti G.C., Ritter J.M. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond) 1993, 85:687-693.
10. Fukuda H., Iritani N., Noguchi T. Transcriptional regulatory regions for expression of the rat fatty acid synthase. FEBS Lett 1997, 406:243-248.
11. Gallagher J.T., Lyon M., Steward W.P. Structure and function of heparan sulphate proteoglycans. Biochem J 1986, 236:313-325.
12. Ha T.S., Song C.J., Lee J.H. Effects of advanced glycosylation endproducts on perlecan core protein of glomerular epithelium. Pediatr Nephrol 2004, 19:1219-1224.
13. Han J., Mandal A.K., Hiebert L.M. Endothelial cell injury by high glucose and heparanase is prevented by insulin, heparin and basic fibroblast growth factor. Cardiovasc Diabetol 2005, 4. [12-Available from URL: http://www.cardiab.com/content/4/1/12].
14. Han J., Woytowich A.E., Mandal A.K., Hiebert L.M. Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin. Exp Biol Med (Maywood) 2007, 232:927-934.
15. Han J., Zhang F., Xie J., Linhardt R.J., Hiebert L.M. Changes in cultured endothelial cell glycosaminoglycans under hyperglycemic conditions and the effect of insulin and heparin. Cardiovasc Diabetol 2009, 8:46.
16. Ishikawa Y., Kitamura M. Inhibition of glomerular cell apoptosis by heparin. Kidney Int 1999, 56:954-963.
17. Ishikawa Y., Yokoo T., Kitamura M. c-Jun/AP-1, but not NF-kappa B, is a mediator for oxidant-initiated apoptosis in glomerular mesangial cells. Biochem Biophys Res Commun 1997, 240:496-501.
18. Jensen T. Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes 1997, 46(Suppl. 2):S98-S100.
19. Jiang P., Kumar A., Parrillo J.E., Dempsey L.A., Platt J.L., Prinz R.A., et al. Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem 2002, 277:8989-8998.
20. Kaji T., Yamada A., Miyajima S., Yamamoto C., Fujiwara Y., Wight T.N., et al. Cell density-dependent regulation of proteoglycan synthesis by transforming growth factor-beta(1) in cultured bovine aortic endothelial cells. J Biol Chem 2000, 275:1463-1470.
21. Kanwar Y.S., Linker A., Farquhar M.G. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 1980, 86:688-693.
22. Kjellen L., Bielefeld D., Hook M. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 1983, 32:337-342.
23. Ko C.W., Bhandari B., Yee J., Terhune W.C., Maldonado R., Kasinath B.S. Cyclic AMP regulates basement membrane heparan sulfate proteoglycan, perlecan, metabolism in rat glomerular epithelial cells. Mol Cell Biochem 1996, 162:65-73.
24. Larrain J., Cizmeci-Smith G., Troncoso V., Stahl R.C., Carey D.J., Brandan E. Syndecan-1 expression is down-regulated during myoblast terminal differentiation. Modulation by growth factors and retinoic acid. J Biol Chem 1997, 272:18418-18424.
25. Levidiotis V., Freeman C., Tikellis C., Cooper M.E., Power D.A. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 2004, 15:68-78.
26. Levidiotis V., Kanellis J., Ierino F.L., Power D.A. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 2001, 60:1287-1296.
27. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
28. Lu W.C., Liu Y.N., Kang B.B., Chen J.H. Trans-activation of heparanase promoter by ETS transcription factors. Oncogene 2003, 22:919-923.
29. Mandal A.K., Lyden T.W., Fazel A., Saklayen M.G., Mehrotra B., Mehling B., et al. Heparin-induced endothelial cell cytoskeletal reorganization: a potential mechanism for vascular relaxation. Kidney Int 1995, 48:1508-1516.
30. Mandal A.K., Puchalski J.T., Lemley-Gillespie S., Taylor C.A., Kohno M. Effect of insulin and heparin on glucose-induced vascular damage in cell culture. Kidney Int 2000, 57:2492-2501.
31. Maxhimer J.B., Somenek M., Rao G., Pesce C.E., Baldwin D., Gattuso P., et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005, 54:2172-2178.
32. Raats C.J., van den B.J., Berden J.H. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000, 57:385-400.
33. Reiland J., Sanderson R.D., Waguespack M., Barker S.A., Long R., Carson D.D., et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 2004, 279:8047-8055.
34. Reizes O., Goldberger O., Smith A.C., Xu Z., Bernfield M., Bickel P.E. Insulin promotes shedding of syndecan ectodomains from 3T3-L1 adipocytes: a proposed mechanism for stabilization of extracellular lipoprotein lipase. Biochemistry 2006, 45:5703-5711.
35. Scivittaro V., Ganz M.B., Weiss M.F. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000, 278:F676-F683.
36. Shih H.M., Towle H.C. Definition of the carbohydrate response element of the rat S14 gene. Evidence for a common factor required for carbohydrate regulation of hepatic genes. J Biol Chem 1992, 267:13222-13228.
37. Svennevig K., Kolset S.O., Bangstad H.J. Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients. Diabetologia 2006, 49:2214-2216.
38. Tamsma J.T., van den B.J., Bruijn J.A., Assmann K.J., Weening J.J., Berden J.H., et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994, 37:313-320.
39. Thompson K.S., Towle H.C. Localization of the carbohydrate response element of the rat L-type pyruvate kinase gene. J Biol Chem 1991, 266:8679-8682.
40. van den Hoven M.J., Rops A.L., Bakker M.A., Aten J., Rutjes N., Roestenberg P., et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006, 70:2100-2108.
41. van Det N.F., van den B.J., Tamsma J.T., Verhagen N.A., Berden J.H., Bruijn J.A., et al. Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int 1996, 49:1079-1089.
42. Vaulont S., Kahn A. Transcriptional control of metabolic regulation genes by carbohydrates. FASEB J 1994, 8:28-35.
43. Vihinen T., Maatta A., Jaakkola P., Auvinen P., Jalkanen M. Functional characterization of mouse syndecan-1 promoter. J Biol Chem 1996, 271:12532-12541.
44. Vogl-Willis C.A., Edwards I.J. High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 2004, 1672:36-45.
45. Wasty F., Alavi M.Z., Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993, 36:316-322.
46. Weigert C., Brodbeck K., Haring H.U., Gambaro G., Schleicher E.D. Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int 2001, 60:935-943.
47. Yang Y., Macleod V., Miao H.Q., Theus A., Zhan F., Shaughnessy J.D., et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007, 282:13326-13333.
48. Yokokawa K., Kohno M., Mandal A.K., Tahara H., Yanagisawa M., Takeda T., et al. Heparin suppresses endothelin-1 peptide and mRNA expression in cultured endothelial cells of spontaneously hypertensive rats. J Am Soc Nephrol 1994, 4:1683-1689.